Earnings

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

By

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Five things for pharma marketers to know: Monday, February 13, 2016

Five things for pharma marketers to know: Monday, February 13, 2016

By

Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits

J2 Global considers divesting parts of Everyday Health

J2 Global considers divesting parts of Everyday Health

By

The company acquired Everyday Health in December.

GSK prepares for Advair competition

GSK prepares for Advair competition

By

If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.

Five things for pharma marketers to know: Monday, February 6, 2017

Five things for pharma marketers to know: Monday, February 6, 2017

By

Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year

Five things for pharma marketers to know: Thursday, February 2, 2017

Five things for pharma marketers to know: Thursday, February 2, 2017

By

Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue

Five things for pharma marketers to know: Wednesday, January 25, 2017

Five things for pharma marketers to know: Wednesday, January 25, 2017

By

Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims

Five things for pharma marketers to know: Tuesday, January 24, 2017

Five things for pharma marketers to know: Tuesday, January 24, 2017

By

Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role

Five things for pharma marketers to know: Thursday, November 10, 2016

Five things for pharma marketers to know: Thursday, November 10, 2016

By

Mylan reports third-quarter loss; analysts say drug-pricing restrictions less likely under Trump; the FDA limits citizen petitions

Five things for pharma marketers to know: Tuesday, November 8, 2016

Five things for pharma marketers to know: Tuesday, November 8, 2016

By

FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast

Five things for pharma marketers to know: Wednesday, November 2, 2016

Five things for pharma marketers to know: Wednesday, November 2, 2016

By

Valeant to sell stomach-drug business for $10 billion; Pfizer reports growth in third quarter; sales of hep.-C drugs drive revenue down for Gilead Sciences

Five things for pharma marketers to know: Tuesday, October 25, 2016

Five things for pharma marketers to know: Tuesday, October 25, 2016

By

Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health

Five things for pharma marketers to know: Friday, July 29, 2016

Five things for pharma marketers to know: Friday, July 29, 2016

By

England's NHS delays hep-C coverage due to pricing; Google reports 21% revenue growth; U.S. and U.K. announce partnership for antibiotic development

Five things for pharma marketers to know: Thursday, July 28, 2016

Five things for pharma marketers to know: Thursday, July 28, 2016

By

Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi's Adlyxin

Huntsworth Health revenue rose 18% in the first half of 2016

Huntsworth Health revenue rose 18% in the first half of 2016

By

Red, a Huntsworth agency, also counted Sanofi as a new client.

Five things for pharma marketers to know: Friday, April 29, 2016

Five things for pharma marketers to know: Friday, April 29, 2016

By

Harvoni and Sovaldi growth begins to slow; drugmakers spend billions to buy developers of cancer therapies; Valeant discloses new investigations

Novartis launches DTC campaign for Entresto

Novartis launches DTC campaign for Entresto

By

The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.

Competition drives down sales of J&J's Olysio

Competition drives down sales of J&J's Olysio

By

The company said growth in its immunology portfolio offset declining Olysio sales.

Novartis: Cardiologists slow to advocate on behalf of new drugs

Novartis: Cardiologists slow to advocate on behalf of new drugs

By

The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.

Pfizer delivers strong Prevnar sales on back of big '15 consumer media outlay

Pfizer delivers strong Prevnar sales on back of big '15 consumer media outlay

By

Company's vaccines chief credits campaigns aimed at grownups with driving US demand for blockbuster vaccine. The remaining cohort will be harder to capture.

Diabetes launches aid Lilly's Q3 sales growth

Diabetes launches aid Lilly's Q3 sales growth

By

The drugmaker recently launched a DTC campaign for diabetes drug Trulicity, which generated $73.7 million in sales in the third quarter.

Novo Nordisk says any tussle with Sanofi's Toujeo will come down to formulary access

Novo Nordisk says any tussle with Sanofi's Toujeo will come down to formulary access

By

The Danish drugmaker said it expects an FDA decision about long-acting—and long-delayed—insulin Tresiba in October.

Merck's Keytruda gains market share in Q2

Merck's Keytruda gains market share in Q2

By

The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.

J&J prepares to defend Remicade market share

J&J prepares to defend Remicade market share

By

Johnson & Johnson CEO Alex Gorsky said physicians are unlikely to switch the majority of patients to a biosimilar version of Remicade.

Weight-loss drug prescriptions rise ... slowly

Weight-loss drug prescriptions rise ... slowly

By

First-quarter results show prescription weight-loss drugs continue to struggle with market and mind share.

Myriad expands companion diagnostic deals

Myriad expands companion diagnostic deals

By

The company partnered with AstraZeneca and BioMarin to identify which patients respond to experimental cancer drugs.

Five things for pharma marketers to know: Friday, May 1

Five things for pharma marketers to know: Friday, May 1

By

Nexium tops the list of Medicare's spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company

Bristol-Myers Squibb sales rise, led by Eliquis and Opdivo

Bristol-Myers Squibb sales rise, led by Eliquis and Opdivo

By

Newly approved Opdivo added $40 million to the quarter's product sales, which rose 8.9% compared to the year-earlier period.

Pfizer reports uptake for cancer-therapy Ibrance

Pfizer reports uptake for cancer-therapy Ibrance

By

Sales of the new cancer drug topped expectations since its February launch.

Lilly sees sales fall but reaffirms 2015 revenue guidance

Lilly sees sales fall but reaffirms 2015 revenue guidance

By

First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.

OPINION

Newsletters